Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 382 results
May 2019
-
Story Discovery
Cancer research drives breast cancer treatment forward
Novartis team perseveres to develop more personalized approach to breast cancer therapy.
-
Story Discovery
Respiratory clinical trials: Putting patients at the heart of research
All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.
-
Story Discovery
Women in Science: Sandrine Piret-Gérard
Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.
April 2019
-
Story Access to Healthcare
Asian health experts call for final push to wipe out deadliest form of malaria
The most lethal strain could be eliminated by 2030, but major hurdles remain.
-
Story
Counting on combos for complex liver diseases
The best treatment for multifaceted diseases like NASH may be combinations of drugs.
-
Story
Bringing gene therapy into focus
Dr. Botond Roska says we should keep our eyes on gene therapy.
March 2019
-
Story From Our Labs
What goes wrong with the window to the soul in glaucoma?
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Story Discovery
Experimental gene therapy discovered in-house enters clinical testing
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
-
Story Discovery
Visualizing immuno-oncology research
Learn how Novartis researchers are working to outsmart tumors.
-
Story People and Culture
Enabling 130,000 employees to grow in an organization committed to continuous learning
Our Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.
-
Story Access to Healthcare
Novartis Access impact evaluation: progress update on our work with Boston University
Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.
